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Osteopontin: A novel regulator at the cross roads
of inflammation, obesity and diabetes
Florian Kahles 1, Hannes M. Findeisen 1,2, Dennis Bruemmer 3,*
ABSTRACT
Since its first description more than 20 years ago osteopontin has emerged as an active player in many physiological and pathological pro-
cesses, including biomineralization, tissue remodeling and inflammation. As an extracellular matrix protein and proinflammatory cytokine
osteopontin is thought to facilitate the recruitment of monocytes/macrophages and to mediate cytokine secretion in leukocytes. Modulation of
immune cell response by osteopontin has been associated with various inflammatory diseases and may play a pivotal role in the development of
adipose tissue inflammation and insulin resistance. Here we summarize recent findings on the role of osteopontin in metabolic disorders,
particularly focusing on diabetes and obesity.
 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. INTRODUCTION
Osteopontin (OPN), also known as secreted phosphoprotein 1 (SPP 1),
44 kDa bone phosphoprotein, sialoprotein 1, 2ar, uropontin, and early
T-lymphocyte activation-1 (Eta-1) is a secreted matricellular protein
that was first identified in 1985 by Heingard et al. as sialoprotein
derived from bovine bone matrix [1]. The most commonly used name
osteopontin is derived from “osteon”, the Greek word for bone, and
“pons”, the Latin word for bridge illustrating its function as a linking
protein and crucial factor in bone homeostasis [2].
OPN is a negatively charged aspartic acid-rich, N-linked glycosylated
phosphoprotein composed of 314 amino acid residues [3e5]. The
human gene for OPN has been localized on the long arm of chromo-
some 4q13 directly related to four similar genes encoding for bone
sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialophos-
phoprotein (DSPP) and matrix extracellular phosphoglycoprotein
(MEPE) [6,7]. Due to common functional motifs and domains these five
integrin-binding glycophosphoproteins are categorized as the so called
SIBLING proteins (small integrin-binding ligand N-linked glycoproteins)
[8]. OPN is encoded by a single copy gene, but exists in various iso-
forms as a result of alternative splicing, alternative translation and
different posttranslational modifications (PTMs), which allow for a
molecular weight ranging from 41 to 75 kDa [9e13]. To date three
splice variants of the human OPN transcript have been identified: OPN
a, the full-length isoform; OPN b which lacks exon 5 and OPN c which
lacks exon 4 [11]. OPN has primarily been described as a secreted
protein involved in several physiological as well as pathological events.
However, current evidence suggests that OPN can also be found in the
cytoplasm and the nucleus [14]. This form of intracellular OPN (iOPN) is
the result of alternative translation and has biological functions distinct
from those of secreted OPN (sOPN) [15].
OPN is expressed in various cell types and tissues including pre-
osteoblasts, osteoblasts, osteocytes [16], chondrocytes [17], fibro-
blasts [18], dendritic cells, macrophages and T-cells [19], hepatocytes
[20], smooth muscle cells [21], skeletal muscle [22], endothelial cells
[23], inner ear [24], brain [25], placenta and mammary glands [26],
deciduum and kidney [5,27]. Extracellular OPN functions through its
interactions with multiple cell surface receptors, including various
integrins (avb1, avb3, avb5, avb6, a4b1, a5b1, a8b1, and a9b1)
and CD44 [15,16] thereby regulating cellular processes such as bio-
mineralization, tissue remodeling and immune regulation [4,28,29].
Abundant evidence suggests that OPN plays a critical role in chronic
inflammatory diseases, including multiple sclerosis [30], Crohn’s
disease [31] and other autoimmune disorders [32,33], several types of
cancer [34e36] and cardiovascular diseases [37e40]. Furthermore,
OPN may play a pivotal role in the development of adipose tissue
inflammation and insulin resistance [29,41]. In this review, we will
summarize the current knowledge on the role of OPN in metabolic
disorders, particularly focusing on diabetes and obesity.
2. OPN IN BIOMINERALIZATION
It is now well recognized that one major physiological function of OPN
is the control of biomineralization. As a member of the SIBLING protein
family with overall negative charge, OPN is able to directly bind to
specific apatite crystal faces thereby governing its function as a
mineralization inhibitor [4,42]. Hence, OPN/ bones unlike those from
wild type mice are hypermineralized and more fragile [4,43].
Furthermore, OPN is not only critical for bone mineralization, but is also
strongly upregulated at sites of ectopic, pathologic calcificatione such
as vascular calcification [44], valvular calcification [45], renal crystal
formation [46], and gallstone formation [47].
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3. OPN IN TISSUE REMODELING PROCESSES
Although it is not required for normal bone formation and development,
OPN participates as an essential component in the bone remodeling
process [48,49]. Bone cells secrete OPN physiologically during the
process of bone remodeling and increase OPN expression in response
to mechanical stimuli [50,51]. OPN appears to stimulate adhesion,
migration and bone resorption by osteoclasts [52]. OPN function in
osteoclasts involves the stimulation of CD44 expression on the oste-
oclast surface, which was shown to be required for osteoclast motility
and bone resorption. Consistently, resorption of ectopic bone is sub-
stantially impaired in the absence of OPN [53]. OPN has also been
shown to regulate remodeling of soft tissues in response to pathologic
stimuli. For example, in heart failure and cardiac remodeling there
appears to be a sophisticated balance of OPN expression: strongly
increased levels of OPN may induce deleterious fibrosis and hyper-
trophy while sufficient levels of OPN are needed to prevent left ven-
tricular (LV) dilatation [37].
4. OPN IN INFLAMMATION
Multiple studies have demonstrated that OPN is expressed by in-
flammatory cells such as macrophages and highly induced during
inflammatory activation [19,54].
OPN appears to be constitutively expressed but in all cells studied it is
rapidly upregulated following cellular activation by a variety of growth
factors and cytokines (including LPS, NO, Ang II, IL-1b, IL-2, IL-3,
IFN-g, TNF-a, TGFb) [55,56]. Until this date the molecular mecha-
nisms that regulate OPN expression in macrophages during inflam-
mation remain incompletely understood. The OPN promoter is
remarkably responsive and contains various motifs including a purine-
rich sequence, an ETS-like sequence, glucocorticoid and vitamin D
response elements, and IFN-inducible elements [57,58]. In LPS-
stimulated macrophages OPN expression was shown to be upregu-
lated by activation of phosphoinositide 3-kinase (PI3K), extracellular
signal-regulated kinase (ERK), and c-Jun NH2-terminal kinase (JNK).
Furthermore, chromatin immunoprecipitation (ChIP) assays revealed
that activator protein 1 (AP-1) binds to the proximal AP-1 site in the
OPN promoter from LPS-stimulated macrophages [59]. We could
demonstrate that cytokine-induced OPN expression in macrophages
depends on AP-1 binding to a CCTCATGAC cognate (AP-1 consensus
element) in the proximal OPN promotor between -80 and -71. Stim-
ulation of macrophages with LXR ligands suppressed cytokine-induced
OPN expression by inhibition of c-Jun/c-Fos DNA binding activities to
the proximal OPN promotor, which impairs AP-1-dependent OPN
transcription [60]. Recent work provided evidence that NF-kB also
plays an important role during LPS-stimulated OPN expression through
binding to a cis-regulatory element (GGAATTCCC between nt e 1817
and nt e 1808) in the distal OPN promotor in macrophages. Inter-
estingly, LPS stimulation induced chromosomal loops in the OPN
promotor between the NF-kB binding site and the AP-1 binding site
involving the coactivator p300. These results identified an essential
mechanism to establish higher order chromatin structure to regulate
LPS-induced OPN expression [61]. Work by Oyama and co-workers
demonstrated that phorbol 12-myristate 13-acetate (PMA)-induced
OPN expression is significantly decreased by troglitazone and other
PPARg ligands in macrophages. Further experiments showed that
PPARg inhibits the OPN promoter activity, and the PPARg-responsive
region within the OPN promoter lies between -1000 and -970 relative
to the transcription start site. Site-specific mutation analysis and
electrophoretic mobility shift assays indicated that a homeobox-like A/
T-rich sequence between -990 and -981, which functions as a binding
site for PMA-induced nuclear factors other than PPARg, mediates the
repression of OPN expression by troglitazone. Moreover, concatenated
A/T-rich sequences conferred the PPARg responsiveness on the het-
erologous promoter. All in all, these data suggest that PPARg ligand
inhibits OPN gene expression through the interference with the binding
of nuclear factors to A/T-rich sequence in macrophages [62].
It is now well recognized that OPN controls immune cell functions
including monocyte adhesion [63], migration [64], differentiation [65],
and phagocytosis [4,15,66]. The induction of monocyte and macro-
phage chemotaxis and cellular motility as well as migration by OPN
occurs via direct interaction with several different cell surface re-
ceptors [67e69]. This interaction is mostly mediated by two different
binding domains. As mentioned above, OPN interacts with avb1,
avb3, avb5, avb6, a8b1 and a5b1 integrins through its RGD domain,
while the SLAYGLR (SVVYGLR in human OPN) domain facilitates
binding to a9b1, a4b1 and a4b7 integrins. Furthermore, OPN has
been identified to interact with the CD44 hyaluronic acid receptor [54].
Additionally, OPN induces the expression of matrix metalloproteinase
(MMP), in particular MMP-2 and MMP-9 [39,64,70]. Since these
proteinases are important in degrading matrix for migrating cells, this
represents an alternative mechanism by which OPN may profoundly
enhance cellular migration. In vivo, evidence for OPN regulating
monocyte/macrophage recruitment to sites of inflammation was pro-
vided by studies using either blocking antibodies or genetic ap-
proaches. Neutralizing antibodies to OPN diminished intradermal
macrophage infiltration in response to a chemotactic peptide [63] and
monocyte migration into joints leading to an inhibition of rheumatoid
arthritis [71]. Impaired leukocyte recruitment in OPN/ mice has
further been demonstrated in a variety of different inflammatory dis-
ease processes [39,72e76]. In all these studies, OPN/ mice
consistently exhibited diminished leukocyte recruitment at sites of
inflammation demonstrating the pivotal role of OPN to regulate
leukocyte attraction during inflammation. OPN is not only critical for
macrophage recruitment, but also regulates the secretion of cytokines
during cell-mediated immunity [4]. OPN itself activates the transcrip-
tion factors NF-kB and AP-1 and thereby potentially modulates the
expression of a variety of inflammatory genes [77]. The engagement of
CD44 and avb3 integrin by OPN induces PI3-kinase dependent Akt
phosphorylation and enhances the interaction between phosphorylated
Akt and IKKa/b. OPN also enhances NF-kB activation through phos-
phorylation and degradation of IkBa by inducing the IKKa/b activity
[78,79]. Furthermore, SFK (Src family of tyrosine kinases) kinase ac-
tivity was found to be required for integrin avb3-mediated NF-kB
activation [80]. OPN-mediated activation of AP-1 is mediated by nu-
clear factor-inducing kinase (NIK)eERK (extracellular signal-related
kinase) and MEKK1 (also known as mitogen-activated protein kinase
kinase kinase 1 (MAP3K1)eJNK1 (also known as MAPK8)) signaling.
Upon binding to avb3, OPN also stimulates epidermal growth factor
receptor (EGFR) transactivation and ERK phosphorylation [8]. Further
studies revealed that OPN regulates crosstalk between NF-kB and AP-
1 by p70S6K/mTOR phosphorylation which is unidirectional towards
AP-1 that in turn regulates intercellular adhesion molecule-1 (ICAM-1)
expression [77].
Polarization of Th cells to the Th1 or Th2 phenotypes, a critical aspect
of cell-mediated immunity, is influenced by OPN which enhances Th1
and inhibits Th2 cytokine expression [75]. OPN induces macrophages
to express IL-12 and stimulates T-cells to express INF-g and CD40
ligand, which subsequently induces IL-12 expression from monocytes
[75,81]. Thus, OPN provides an important early stimulus for IL-12
production at sites of inflammation. OPN further inhibits IL-10
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expression by macrophages and thereby decreases anti-inflammatory
signaling pathways [39,75]. Collectively, these in vivo studies support
altered innate immune responses in OPN/ mice, consistent with the
well-described regulation of monocyte/macrophage migration and
invasion by OPN, and point to an underappreciated role of OPN as a
potent mediator of cellular immunity (Figure 1).
5. OPN IN OBESITY AND DIABETES
Obesity constitutes the major risk factor for the development of insulin
resistance, type 2 diabetes and subsequent diabetes-related compli-
cations such as micro- and macrovascular disease [82]. Chronic low-
grade inflammation has been described as a fundamental component
of adipose tissue expansion in obesity. Inflamed adipose tissue is
characterized by enhanced secretion of cytokines and recruitment of
leukocytes, in particular macrophages [83]. Current evidence suggests
that these cytokines, often referred to as adipokines, including resistin,
visfatin, apelin, omentin, chemerin, IL-6, MCP-1, PAI-1, or TNF-a link
obesity to the development of systemic insulin resistance [84]. Several
studies have described OPN as a critical regulator of adipose tissue
inflammation, insulin resistance and diabetes mellitus (Figure 2). OPN
expression is drastically upregulated by 40 and 80-fold in adipose
tissue from diet-induced and genetically obese mice, respectively [85].
Furthermore, mice exposed to a high-fat-diet (HFD) exhibited elevated
OPN expression in macrophages recruited to the adipose tissue [29].
Using loss-of function approaches we [29] and others [41] reported
that HFD-induced adipose tissue macrophage infiltration and inflam-
matory gene expression were markedly blunted in OPN/ mice [29].
A similar phenotype could be observed following treatment with an
OPN-neutralizing antibody [29,41]. Adipose tissue expression of IL-6,
TNF-a, MCP-1 and iNOS as well as IL-6, MCP-1 and PAI-1 plasma
levels were significantly reduced in mice lacking the OPN gene [29].
Importantly, OPN deficiency not only led to decreased adipose tissue
inflammation, but also improved whole-body glucose tolerance and
reduced insulin resistance in mice independent from body composition
or energy expenditure [29,41]. This protection from metabolic deteri-
oration by OPN depletion is already apparent after only two weeks of
HFD feeding [86].
Although OPN protein expression can be induced by a variety of growth
factors and cytokines [55], the mechanisms by which OPN is upre-
gulated in adipose tissue inflammation remains incompletely under-
stood. Analysis of adipose tissue cellular fractions revealed that the
main source of OPN in human and murine genetic and diet-induced
obesity are adipose tissue macrophages (ATM) [29,85]. First mecha-
nistic insights were provided by Samuvel et al. who incubated
mononuclear cells with adipocytes in a transwell system and studied
how cell interaction regulated OPN expression. OPN expression in
mononuclear cells was markedly increased when cocultured with
Figure 1: OPN is secreted by activated macrophages and T-cells and has been shown to be an important component of early cellular immune responses and inflammation. These proinflammatory
effects of OPN are mediated through engagement of a number of receptors. Of particular interest are the integrin receptor avb3 and the CD44 receptor. Ligation to these receptors results in important
proinflammatory functions allowing OPN to mediate the recruitment and activation of leukocytes at sites of inflammation.
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adipocytes. In addition, LPS-induced TLR4 activation and high glucose
further augmented coculture-stimulated OPN secretion. Neutralizing
antibodies against IL-6 or siRNA mediated IL-6 knockdown in adipo-
cytes diminished LPS mediated OPN expression in mononuclear cells
in coculture with adipocytes. These results suggest, that IL-6 released
from adipocytes might regulate OPN secretion from immune cells
during adipose tissue inflammation [87]. Recently, Lu et al. showed
that macrophage-specific growth hormone (GH) receptor-null mice
(MacGHR KO) challenged with HFD exhibited impaired glucose and
insulin tolerance, which was paralleled by increased adipose tissue
inflammation and OPN expression. Further experiments established
that GH, acting via a NF-kB site in the distal OPN promotor directly
inhibits OPN promoter activity and expression [88]. Therefore admin-
istration of GH could have beneficial effects on HFD-induced adipose
tissue inflammation and insulin resistance.
Although OPN expression during adipose tissue inflammation is pri-
marily mediated by immune cells, recent work shows that the incretin
hormone GIP (Glucose dependent insulinotropic peptide) increases OPN
expression in primary adipocytes. Mechanistically, GIP-induced upre-
gulation of OPN expression is mediated by a crosstalk with insulin
signaling pathways, the transcriptional factor NFAT and the cAMP/
PDE3B system [83,89]. Remarkably, a genetic variant with reduced GIP
receptor function is correlated with lower OPN expression and improved
insulin sensitivity in humans [83]. Both studies suggest a novel link
between the incretin hormone GIP and OPN regulation in adipose tissue.
All these findings provide novel insights into the regulation of OPN
expression in adipose tissue and support further research to elucidate
the distinct molecular pathways regulating OPN secretion during HFD-
induced obesity.
Until this date not much is known about the pathophysiological impact
of the different OPN isoforms in terms of leukocyte recruitment and
cytokine signaling in adipose tissue. Recent evidence suggests that
highly phosphorylated OPN isoforms have significantly reduced ca-
pabilities to promote cell adhesion via the avb3-integrin receptor [90].
Further studies showed upregulation of alkaline phosphatases during
adipogenesis [91] and revealed altered OPN isoform expression in
adipose tissue following high-fat feeding [86]. These first clues sug-
gest that the phosphorylation state of different OPN isoforms might
regulate OPN function during adipose tissue inflammation in terms of
diet-induced obesity. Future studies are greatly needed to confirm this
hypothesis.
Further approaches analyzed whether OPN could be causally involved
in the pathogenesis of type 2 diabetes. First clues were provided by
studies of Chapman et al. revealing a reduction of HFD-induced
hyperleptinemia and reduced adipocyte hypertrophy in OPN/ mice
[86]. In human adipose tissue several OPN receptor chains have been
detected on adipocytes and non-adipocytes at high levels. In contrast
to integrin chains av, b1, and b5, which are expressed in adipocytes,
in the adipose-derived stromal vascular fraction (dSVF) and in ATM, a9
and CD44 were expressed only in non-adipocytes (dSVC). Integrins a4
and a8 were selectively detected in ATM and dSVC, respectively. The
b3 chain was only marginally found exclusively in dSVC. Interestingly,
OPN was found to directly stimulate inflammatory signaling pathways
and secretion of cytokines in isolated human adipose tissue macro-
phages and adipocytes [92]. Analysis of signaling molecules revealed a
substantial phosphorylation of Akt, p38 MAPK, and ERK, as well as
degradation of IkB-a following OPN stimulation in human macro-
phages, whereas phosphorylation of JNK was only less affected. OPN
Figure 2: During diet-induced weight gain OPN is upregulated and mediates macrophage infiltration into adipose tissue. OPN expression in adipose tissue macrophages is enhanced by high glucose,
TLR4 activation, IL-6 and IL-18. In adipocytes GIP increases OPN secretion. OPN itself activates several inflammatory signaling pathways leading to adipose tissue insulin resistance and type 2 diabetes.
Furthermore, OPN was shown to directly increase atherosclerosis, NAFLD, NASH and diabetic nephropathy.
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further upregulates TNF-a and MCP-1 expression in human macro-
phages. In human adipocytes OPN impaired differentiation and insulin
sensitivity of primary adipocytes as determined by peroxisomal
proliferator-activated receptor-g (PPARg) and adiponectin gene
expression and insulin-stimulated glucose uptake. Furthermore, in
adipocytes OPN induces phosphorylation of JNK and ERK while leaving
the NF-kB pathway as well as phosphorylation of Akt and p38 MAPK
virtually unaffected [92]. These results identified OPN as a key
component in the development of HFD-induced insulin resistance.
Since OPN has been established as a crucial component in the
development of experimental adipose tissue inflammation and insulin
resistance, a number of human studies have focused on its role in
patients with obesity and type 2 diabetes. First clinical approaches
yielded results similar to rodent studies. Likewise, OPN expression in
adipose tissue as well as circulating OPN levels were substantially
elevated in obese patients compared with lean subjects, and were
further increased in obese diabetic or insulin resistant patients [85,93e
95]. Conversely, dietary weight loss significantly decreased OPN con-
centrations [93,96]. Surprising results were found in four studies
analyzing OPN levels in morbidly obese patients before and after bar-
iatric surgery. Subjects who previously underwent gastric banding or
Roux-en Y gastric bypass exhibited decreased body weight, body mass
index, inflammation markers as well as reduced insulin resistance.
However, all studies consistently reported a gradual increase of OPN
blood concentrations after bariatric surgery [97e100]. Further in-
vestigations are needed to differentiate whether these changes are
secondary to alterations of bone metabolism or an adaption to weight
loss. We previously demonstrated that OPN expression in human
macrophages is upregulated by a variety of proinflammatory mediators
known to be elevated in type 2 diabetes and cardiovascular disease,
including TNF-a, IL-6, and oxidized LDL [101]. This induction of OPN
expression in macrophages was suppressed by the PPARa ligands
bezafibrate and WY14643 through a mechanism involving an inhibition
of AP-1-dependent transactivation of the proximal OPN promoter.
Finally, using a translational approach we observed decreased OPN
plasma levels in type 2 diabetic patients after short-term treatment with
bezafibrate [101]. More recently, Ahmad et al. reported simultaneous
upregulation of IL-18 and OPN in PBMCs (peripheral blood mononuclear
cells) from obese individuals compared to lean group. Intriguingly,
treatment with a neutralizing IL-18 antibody diminished OPN secretion
from PBMCs, indicating that IL-18 regulates OPN expression [94].
These findings point toward a specific pathophysiological role of OPN
also in human inflammatory processes linked to obesity-induced adi-
pose inflammation and insulin resistance. Therefore, pharmacological
inhibition of OPN expression might be a novel approach for the treat-
ment of type 2 diabetes and its complications.
As mentioned above it has been widely accepted that local OPN
expression is strongly elevated in adipose tissue during the
development of HFD-induced obesity [29,85,93]. However, several
approaches analyzing systemic circulating OPN levels yielded incon-
clusive results. We and others found a slight but significant increase of
systemic OPN levels in HFD-induced obese mice [29,97], whereas
another group reported no difference in OPN plasma levels in a murine
model of diet-induced obesity [85]. Nevertheless, a number of human
studies consistently reported elevated circulating OPN levels in obese
individuals compared with lean subjects [85,93,94,97]. Surprisingly,
although weight loss was paralleled by a decrease of circulating OPN
levels, there was no correlation between serum OPN and body fat
percentage [96]. Kiefer and co-workers further showed that OPN
expression in adipose tissue is not correlated with plasma OPN levels
in obese patients [85]. This was strengthened by work from Bertola
et al. who reported a substantial increase of circulating OPN levels
despite downregulation of local OPN expression in white adipose tissue
in obese patients who underwent bariatric surgery [97]. Consistently,
elegant studies analyzing arteriovenous differences across adipose
tissue from obese subjects revealed that adipose tissue does not se-
cret OPN [97], indicating that local concentrations of OPN in adipose
tissue do not appear to affect its systemic levels. Future studies are
greatly needed to reveal the organ origin of circulating OPN levels in
diet-induced obesity.
6. OPN IN NASH
Obesity and type 2 diabetes are strongly associated with a spectrum of
hepatic disorders collectively referred to as non-alcoholic fatty liver
disease (NAFLD). NAFLD spans a spectrum from simple hepatic
steatosis to non-alcoholic steatohepatitis (NASH) and steatofibrosis
ultimately leading to liver cirrhosis and hepatocellular carcinoma [97].
Notably, OPN expression is also markedly upregulated in the liver in
obesity, and hepatic OPN levels correlate with liver triacylglycerol
levels [97,102]. Within the liver, increased OPN expression was mainly
found in hepatocytes and inflammatory cells [103]. In addition, studies
from Sahai et al. suggest a role for OPN in the development of NAFLD in
mice fed a methionine- and choline-deficient diet [104,105]. This was
further supported by three experimental studies demonstrating that
antibody-mediated OPN neutralization and OPN deficiency protect
against HFD-induced hepatic macrophage infiltration [41,102] and D-
galactosamine-induced inflammatory liver injury [103]. Consistently,
OPN/ mice were protected from obesity-induced hepatic steatosis
which was mediated, at least in part, through diminished hepatic tri-
acylglycerol synthesis. Euglycemicehyperinsulinemic clamp studies
exhibited that insulin resistance and excess hepatic gluconeogenesis
in obesity were significantly attenuated in OPN/ mice. OPN defi-
ciency markedly improved hepatic insulin signaling as shown by
enhanced Akt and IRS-2 (insulin receptor substrate-2) phosphorylation
and prevented upregulation of the major hepatic transcription factor
FOXO1 (Forkhead box O1) and its gluconeogenic target genes [102].
Further experiments showed that OPN reduces activation of hepatic
signal transducer and activator of transcription 3 (STAT3), which is
essential for glucose homeostasis and insulin sensitivity. Additionally,
OPN neutralization diminished expression of hepatic gluconeogenic
markers including phosphoenolpyruvate carboxykinase (PEPCK) and
glucose 6 phosphatase (G6P) [41]. Collectively, these results identified
OPN as an important mediator of obesity-associated hepatic inflam-
mation, steatosis and insulin resistance.
7. OPN IN DIABETIC NEPHROPATHY
During the last decade a number of studies analyzed the role of OPN in
the pathogenesis of diabetic nephropathy. At first, OPN has been re-
ported to be highly expressed in the tubular epithelium of the renal
cortex and in glomeruli in rat and mouse models of diabetic ne-
phropathy [106e108]. This was associated with extensive macro-
phage accumulation in the kidney interstitium indicating that OPN
upregulation and macrophage recruitment may play a role in the
tubulo-interstitial injury in diabetic nephropathy [107]. Consistently,
OPN/ mice are protected from diabetes-induced albuminuria and
renal damage, possibly by modulating podocyte signaling and motility
[109]. In humans, plasma OPN levels are independently associated
with the presence and severity of diabetic nephropathy [110].
Compelling evidence in the literature provides interesting clues about a
link between the renineangiotensin system (RAS) and OPN in diabetic
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kidney disease. Diabetes-induced OPN expression and macrophage
accumulation in the kidney interstitium of diabetic rats are significantly
ameliorated after treatment with the long acting ACE inhibitor peri-
ndopril [107]. This was further supported by work from Li et al.
showing that treatment with ramipril for nine month improves creati-
nine clearance rate and decreases urinary protein excretion, systolic
blood pressure, development of glomerulosclerosis, tubulo-interstitial
fibrosis and inflammatory cell infiltration in a diabetic rat model. Of
note, all these effects of ACE inhibition were associated with markedly
suppressed OPN expression, suggesting that blockade of the RAS by
ramipril may confer renoprotection by decreasing OPN secretion in
diabetic nephropathy [111]. Liver X receptors (LXRs) have been
identified as important lipid-dependent regulators of glucose meta-
bolism and immune functions in leukocytes [112]. Synthetic LXR li-
gands can inhibit cytokine-induced OPN expression in macrophages
[60]. Tachibana and colleges recently observed decreased urinary
albumin excretion and substantially attenuated macrophage infiltra-
tion, mesangial matrix accumulation and interstitial fibrosis in
streptozotocin-induced diabetic mice following administration of the
LXR agonist T0901317. Notably, this was paralleled by diminished
OPN expression in the kidney cortex indicating that inhibition of renal
OPN by LXR activation may provide a potential therapeutical approach
for diabetic nephropathy [113].
8. OPN IN TYPE 1 DIABETES
Apart from its role in obesity-induced adipose tissue inflammation and
insulin resistance, OPN has also been described as a novel protective
islet protein in type 1 diabetes, which is upregulated in rat pancreatic
islets and ducts during beta cell destruction following administration of
streptozotocin (STZ). OPN blunted STZ-induced cytotoxicity, partly via
an RGD-dependent NO regulatory mechanism [114]. Furthermore, OPN
prevented apoptosis and stimulated cell proliferation in human insulin-
secreting cells. Interestingly, the incretin hormone GIP showed similar
effects in beta cells and additionally stimulated OPN expression,
suggesting a link between GIP and OPN in preservation of functional
beta cell mass in humans [115]. On the other hand genetic studies of
single nucleotide polymorphisms in humans suggest that the OPN
encoding gene might be associated with an increased susceptibility to
the development of type 1 diabetes [116,117]. These observations
emphasize the pleiotropic effects and the versatile character of OPN
and support further research to understand the specific role of OPN
during the pathogenesis of type 1 diabetes.
9. PHARMACOLOGICAL INTERVENTIONS
Since many studies emphasized OPN as a crucial mediator of diet-
induced adipose tissue inflammation, insulin resistance, type 2 dia-
betes, NASH/NAFLD and diabetic nephropathy, targeting OPN could
provide a novel approach for the treatment of obesity-related metabolic
disorders. Several studies using loss-of-function approaches already
demonstrated the value of OPN as a therapeutic target in preclinical
animal models [29,41]. Thus, silencing OPN using siRNA and short
hairpin RNA (shRNA) technology, or specific antibodies neutralizing
OPN might provide potential targets. Furthermore, inhibition of OPN
expression by PPARa ligands, PPARg agonists, ACE inhibitors, LXR
agonists, GH and IL-18 neutralizing antibodies might be potential
pharmacological interventions. Since OPN is upregulated by the
incretin hormone GIP, antagonism of the GIP receptor with (Pro3)GIP
could also be a therapeutic target for the treatment of metabolic ab-
normalities [118]. Because OPN acts through several receptor
mechanisms including both integrins and CD44, targeting these re-
ceptor ligand interactions as already under investigation in cancer
therapy might be of interest also for the treatment of type 2 diabetes
[8]. Current data justify speculation that OPN could be a viable target
for new antidiabetic therapies.
10. CONCLUSIONS
Since its first description in the 1980’s OPN has been identified as a
key regulator of many metabolic and inflammatory diseases
including obesity, diabetes, diabetic nephropathy, NAFLD and car-
diovascular disease. Particularly, the use of OPN-deficient murine
models significantly enhanced our understanding of OPN and its role
in various metabolic pathologies. However, several key questions
remain. What are the exact molecular mechanisms of OPN-medi-
ated adipose tissue inflammation and insulin resistance? What is
the impact of different OPN splice variants and isoforms in terms of
leukocyte recruitment and cytokine signaling in adipose tissue?
Furthermore, while OPN has been widely accepted as being causally
involved in the pathogenesis of insulin resistance and type 2 dia-
betes, several studies identified OPN as a protective islet protein
preserving insulin secretion. Therefore, these seemingly conflicting
data demand further research to define the specific role and
function of OPN in the development of diabetes. Especially the
recent identification of a previously unrecognized crosstalk between
OPN and the incretin system in terms of insulin resistance and beta
cell function might open new avenues for future therapeutic
strategies.
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